Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

NDAQ:AUPH - Post by User

Aurinia Pharmaceuticals Inc > Buyout?

<< Previous

Bullboard Posts

Next >>

Comment by jboom70on Oct 26, 2021 5:10am

160 Views

Post# 34048314

RE:RE:RE:Buyout?

Current Sp was heavily manipulated by short sellers.

Treatment is est @ $62000 yr but Ive also seen $90000as a price. Gets big fast with decent market penetration, say 30% of 300,000 and that's just one yr. Plus you have lic in other countries. A large Pharm Co. could also push more Ins. Co's acceptance.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023